Vimarsana
Biggest News Aggregation in the World

Page 15 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

Lai Wang Sells 1,108 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock - Vimarsana News

Lai Wang Sells 1,108 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) insider Lai Wang sold 1,108 shares of the business’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $181.92, for a total value of $201,567.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can […]

Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) Major Shareholder Sells 273,728 Shares of Stock - Vimarsana News

Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) Major Shareholder Sells 273,728 Shares of Stock

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) major shareholder Advisors Ltd. Hhlr sold 273,728 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $207.72, for a total transaction of $56,858,780.16. Following the completion of the sale, the insider now directly owns 142,888,241 shares of […]

Advisors Ltd. Hhlr Sells 273,728 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock - Vimarsana News

Advisors Ltd. Hhlr Sells 273,728 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) major shareholder Advisors Ltd. Hhlr sold 273,728 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $207.72, for a total transaction of $56,858,780.16. Following the sale, the insider now owns 142,888,241 shares in the company, […]

Source: wkrb13.com
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against BeiGene, Ltd. (BGNE) - Vimarsana News

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against BeiGene, Ltd. (BGNE)

The law firm of Kirby McInerney LLP is investigating potential claims against BeiGene Ltd. . The investigation concerns whether BeiGene and/or certain of its officers have violated the federal... | June 16, 2023

AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent - Vimarsana News

AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent

BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc (NYSE: ABBV) company. As per a Bloomberg Law report, AbbVie filed a lawsuit against the China-based company alleging a patent violation related to Brukinsa. "BeiGene's work is original, and we will vigorously defend against all allegations of patent inf

Source: yahoo.com